1. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.
- Author
-
Buggins AG and Pepper CJ
- Subjects
- Antineoplastic Agents pharmacokinetics, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Apoptosis drug effects, Cell Membrane Permeability, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Gene Targeting, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Mitochondrial Membranes physiology, Models, Biological, Multigene Family, Neoplasm Proteins antagonists & inhibitors, Protein Structure, Tertiary, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Proto-Oncogene Proteins c-bcl-2 classification, Reactive Oxygen Species metabolism, Apoptosis physiology, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Neoplasm Proteins physiology, Proto-Oncogene Proteins c-bcl-2 physiology
- Abstract
Bcl-2 family proteins have long been implicated in the pathology of chronic lymphocytic leukaemia (CLL). Indeed, a number of these proteins have been shown to have prognostic importance in this disease. The precise ways in which these proteins impact upon CLL and the ways in which they are regulated remain incompletely resolved. However, significant advances have been recently made in our understanding of how these proteins are controlled by genetic, epigenetic and microenvironmental cues. Furthermore, major progress has been made in trying to target these proteins therapeutically. Here we review the current knowledge about this family of apoptosis-regulating proteins and how they impact upon drug resistance and disease progression. We also summarise evolution in the development of Bcl-2 family inhibitors for the treatment of CLL and other cancers., (Copyright 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF